Story perspectives

MHRA Approves Wegovy Tablet, 13.6% Trial Weight Loss

6/11/2026

Summary

MHRA Approves

The MHRA approved Novo Nordisk’s semaglutide (Wegovy) tablet for weight loss on 11 June 2026.
It may be prescribed to adults with BMI >= 30 kg/m² or BMI 27–30 kg/m² plus a weight-related comorbidity.
The schedule starts at 1.5 mg daily, escalates to 4 mg, 9 mg, then 25 mg, and lets injection users switch directly to the 25 mg tablet.
The OASIS 4 trial showed the 25 mg dose cut weight by 13.6 % after 64 weeks, while NHS adoption awaits NICE assessment.

Summary

Novo Nordisk Approval

Novo Nordisk’s shares rose 2% in morning trading after the MHRA approved the Wegovy oral pill.
The United Kingdom becomes the first European nation to authorize the Wegovy oral pill.
Analysts project the global obesity-drug market will exceed $100 billion annually within a decade, intensifying competition with Eli Lilly’s oral candidate Foundayo.
Novo plans to launch the tablet through private channels within weeks while the NHS awaits NICE evaluation.

1 of 2

MHRA Approves

The MHRA approved Novo Nordisk’s semaglutide (Wegovy) tablet for weight loss on 11 June 2026.
It may be prescribed to adults with BMI >= 30 kg/m² or BMI 27–30 kg/m² plus a weight-related comorbidity.
The schedule starts at 1.5 mg daily, escalates to 4 mg, 9 mg, then 25 mg, and lets injection users switch directly to the 25 mg tablet.
The OASIS 4 trial showed the 25 mg dose cut weight by 13.6 % after 64 weeks, while NHS adoption awaits NICE assessment.

1 / 2